Medicare drug price negotiation: With the first cycle where Part B drugs are eligible to be selected, the implications extend far beyond simple price reductions.

Deeper discounts in the latest round of negotiated prices for Medicare Part D drugs may indicate how future negotiations will play out.

We discuss five key considerations for manufacturers negotiating Medicare Part D formulary access in the wake of the Inflation Reduction Act.

We provide some insights on Medicare price negotiation's year-two selection, which expands to new therapeutic areas.